Prostate Cancer News and Research

Latest Prostate Cancer News and Research

New research finds bisphenol A in fetal liver tissues

New research from the University of Michigan School of Public Health found BPA, or bisphenol A, in fetal liver tissue, demonstrating that there is considerable exposure to the chemical during pregnancy.

4 Dec 2012

Certain patients with prostate cancer may benefit from Provenge clinical trial

Select patients with advanced prostate cancer may benefit from a Georgia Health Sciences University Cancer Center clinical trial that looks to improve survival rates of the FDA-approved prostate cancer drug Provenge.

4 Dec 2012

Enzalutamide shows promise in treating triple-negative and estrogen-positive breast cancer

Breast cancers are defined by their drivers - estrogen and progesterone receptors (ER and PR) and HER2 are the most common, and there are drugs targeting each. When breast cancer has an unknown driver, it also has fewer treatment options - this aggressive form of breast cancer without ER, PR or HER2, which was thought not to be driven by hormones, is known as triple negative.

3 Dec 2012

Single-dose radiotherapy best for painful spine metastases

Research supports the use of single-fraction radiotherapy for the treatment of painful vertebral bone metastases.

3 Dec 2012

Men should see a doctor and be proactive about their health, say UAB experts

Experts at the University of Alabama at Birmingham (UAB) say a man's tendency to wait until the onset of sickness to see his doctor is a major detriment to health because key screenings are missed.

1 Dec 2012

Palliative care needs expanding

Individuals with late-stage Parkinson's disease and other related motor disorders experience severe symptoms of physical and psychologic distress, suggesting that current care is falling short, say UK researchers.

29 Nov 2012

Cancer-related fatigue and exercise: an interview with Dr Fiona Cramp

It is likely that there is more than one reason why people with cancer experience fatigue. The causes are likely to include side effects of the treatment that people are receiving for cancer as well as the direct effects of the cancer.

28 Nov 2012

Dutasteride delays PSA progression

The 5α-reductase inhibitor, dutasteride, delays the clinical progression of prostate cancer in patients with prostate-specific antigen levels that have failed to reduce adequately following radical therapy for localized disease, report researchers.

28 Nov 2012

Hospice patients accepting of student examinations

The majority of hospice inpatients are happy to be examined by medical students, indicate the results of a UK study.

28 Nov 2012

Post-prostatectomy erectile dysfunction treatment disliked

Less than half of men who initiate intracorporeal injections for post-prostatectomy erectile dysfunction are still satisfied with the treatment years later, report researchers.

27 Nov 2012

Leading urologic oncologist explains bladder cancer basics

An unhappy bladder won't be ignored. Frequent urination, pain while urinating, burning while urinating, blood in the urine, and even back pain or pelvic pain can all be symptoms of bladder cancer or other urinary tract problems. The trick, however, is that the absence of urinary symptoms doesn't guarantee a healthy bladder.

27 Nov 2012

Researchers discover LSD-1 enzyme as important target for treatment of Ewing sarcoma

Discovery of a new drug with high potential to treat Ewing sarcoma, an often deadly cancer of children and young adults, and the previously unknown mechanism behind it, come hand-in-hand in a new study by researchers from Huntsman Cancer Institute (HCI) at the University of Utah. The report appears in today's online issue of the journal Oncogene.

26 Nov 2012

Two new studies explore how laws, advertising impact cancer costs

Reuters reports on two new studies regarding cancer treatment costs, including findings that laws don't curb the use of pricey prostate cancer treatments and that ads don't increase the use of aromatase inhibitors for breast cancer.

26 Nov 2012

mRNA vaccines offer protection against influenza A virus infections in various animal models

CureVac GmbH, a clinical stage biopharmaceutical company developing a new class of therapies and vaccines based on mRNA, and the German Federal Research Institute for Animal Health, Friedrich-Loeffler-Institute (FLI), Germany, today announced that mRNA vaccines (RNActive) based on the company's RNA technology platform have the potential to provide effective protection against infectious diseases.

26 Nov 2012

Factors influencing pain in head and neck cancer patients clarified

Individuals with head and neck cancer frequently report pain 1 year after diagnosis, despite being treated with analgesics, show US study results.

22 Nov 2012

Homing beacon drugs can kill cancer cells

A medical researcher with the University of Alberta and his team just published their findings about their work on developing 'homing beacon drugs' that kill only cancer cells, not healthy ones, thanks to nano-technology.

22 Nov 2012

Exercise relieves cancer fatigue

A review of studies spanning 45 years shows that exercise, particularly aerobic rather than strength- or flexibility-based training, improves fatigue in cancer patients.

21 Nov 2012

Fujirebio, Thermo Fisher sign license agreement for broad availability of PCT testing

Thermo Fisher Scientific Inc., the world leader in serving science, today announced it has signed a long-term license agreement with Fujirebio Inc. to make its biomarker assay Procalcitonin (PCT) available on the Lumipulse family of laboratory instruments, using the chemiluminescent enzyme immunoassay (CLEIA) technology.

From Thermo Fisher Scientific Inc. 21 Nov 2012

Janssen receives positive opinion from EMA CHMP for ZYTIGA to treat mCRPC

Janssen-Cilag International NV (Janssen) announced today that the Committee for Medical Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending approval of the oral, once-daily medication ZYTIGA for use in combination with prednisone or prednisolone in the treatment of metastatic castration-resistant prostate cancer (mCRPC), in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy and in whom chemotherapy is not yet clinically indicated.

19 Nov 2012